Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immune cell therapy takes on tough lung cancer

NCT ID NCT07249879

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 12, 2026 · Updated 22 times

Summary

This early study tests a new treatment called GC511B for adults with a type of lung cancer that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR T cells) to target a protein called DLL3 on cancer cells. The main goals are to check safety and see if the therapy can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Gobroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102206, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cancer Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY SMALL CELL LUNG CANCER